FORMATO EUROPEO PER IL CURRICULUM VITAE

INFORMAZIONI PERSONALI

Nome	**DANIELA MARIA ROSSI**
Indirizzo professionale	Laboratorio di Ricerca sulle Malattie Neurodegenerative Istituti Clinici Scientifici Maugeri SpA SB – Istituto di Pavia Via Salvatore Maugeri, 10 27100 Pavia

ESPERIENZA LAVORATIVA

2009-presente	Responsabile del **Laboratorio di Ricerca sulle Malattie Neurodegenerative** presso il Centro di Medicina Molecolare degli **Istituti Clinici Scientifici Maugeri Spa SB** – Pavia.
2002-2009	Post-doc e senior scientist presso i laboratori del Centro di Eccellenza sulle Malattie Neurodegenerative del Sistema Nervoso Centrale e Periferico al Dipartimento di Scienze Farmacologiche, **Università degli Studi di Milano**.
1999-2002	Proseguimento dell'attività di ricerca presso l' MRC Prion Unit and Institute of Neurogenetics, **Imperial College School of Medicine at St. Mary's**, Londra (Regno Unito).
1997-1999	Proseguimento dell'attività di ricerca presso l'Institut für Molekularbiologie, **Università di Zurigo** (Svizzera).
1995-1997	Proseguimento dell'attività di ricerca presso l'Istituto di Scienze Farmacologiche, **Università degli Studi di Milano**.
1994-1995	Internato biennale di laurea nei laboratori del Centro di Neurofarmacologia presso l'Istituto di Scienze Farmacologiche, **Università degli Studi di Milano**.

ISTRUZIONE E FORMAZIONE

2012 - 2016	Conseguimento dell' Abilitazione Scientifica Nazionale alla funzione di professore universitario di II fascia in **Anatomia Umana** (BIO/16-05/H1), **Anatomia Comparata e Citologia** (BIO/06-05/B2), **Biochimica Generale** (BIO/10-05/E1), **Biologia Molecolare** (BIO/11-05/E2), **Biologia Applicata** (BIO/13-05/F1), **Patologia Generale e Patologia Clinica** (MED/04-06/A2)
2002	Riconoscimento da parte del Ministero dell'Istruzione, dell'Università e della Ricerca dell'equipollenza del titolo di "*Doktorin der Naturwissenschaften*" conseguito presso l'Università di Zurigo a Dottorato di Ricerca dell'ordinamento universitario italiano.
2001	Conseguimento del titolo di "Doktorin der Naturwissenschaften", Università di Zurigo.
1997	Conseguimento della specializzazione in Farmacologia (votazione 70/70 lode), conseguita presso l'Università degli Studi di Milano.
1996	Abilitazione all'esercizio della professione di Farmacista conseguita presso l'Università degli Studi di Milano.
1995	Conseguimento della laurea in Chimica e Tecnologie Farmaceutiche (votazione: 110/110), Università degli Studi di Milano.

RICONOSCIMENTI

2012	Best Platform Presentation Award a "10th Annual ENCALS Meeting", Dublino (Irlanda)
2006-2009	Membro del Consiglio Scientifico del Centro di Eccellenza sulle Patologie Neurodegenerative del Sistema Nervoso Centrale e Periferico dell'Università di Milano
2005	Chiron Young Prion Scientist Award
2002-2005	EMBO Long Term Fellowship (279-2002)

BREVETTI

2014	U.S. Patent (No. US 8,778,884 B2): "Glioprotectant Peptide for Use in the Treatment of Amyotrophic Lateral Sclerosis (ALS) and Methods Related Thereto"
2018	Deposito domanda di brevetto PCT (No. PCT/IB2018/050425; EP18702344.5): "Biologically active fusion peptide for use in the treatment of Spinal Muscular Atrophy (SMA)"

TERZA MISSIONE

2009	Presentazione "Meccanismi molecolari della SLA: studi in modelli animali" all'incontro dell'Associazione Italiana Sclerosi Laterale Amiotrofica (AISLA Onlus Asti)
2018	Campagna 5x1000 della Fondazione Salvatore Maugeri a sostegno della ricerca scientifica (https://www.youtube.com/watch?v=Vqgs51z1wxc) (Pavia)
2019	Presentazione del libro "Il mio viaggio nella SLA. Un percorso di conoscenza e condivisione dei problemi dei malati" di Antonio Pinna press oil Centro Puecher-Biblioteca Chiesa Rossa (Milano).
2019	Presentazione "Malattie Neurodegenerative: innovazioni per la diagnosi e la cura" per la "Notte dei Ricercatori" presso gli Istituti Clinici Scientifici Maugeri (Pavia).

ATTIVITA' DIDATTICA

2002-2007	Cultore della materia in Biotecnologie Farmacologiche, Università degli Studi di Milano
2005-2006	Cultore della materia in Neuropsicofarmacologia, Università degli Studi di Milano
2006-2009	Cultore della materia in Farmaci per Malattie Rare, Università degli Studi di Milano
2017	Membro di commissione di dottorato presso l'Université catholique de Louvain (Belgium)
2002-presente	Correlatore di 16 tesi sperimentali in Biotecnologie del Farmaco, Chimica, Chimica e Tecnologie Farmaceutiche, Farmacia, Neurobiologia, Biologia Sperimentale e Applicata Supervisore scientifico di due tesi sperimentali in Scienze Biologiche e di due tesi di dottorato in Scienze farmacotossicologiche, farmacognostiche e biotecnologie farmacologiche.

ATTIVITA' EDITORIALE E DI REVISORE

RIVISTE	Nature Neuroscience, Cell, Annals of Neurology, Progress in Neurobiology, Journal of Neuroscience, Neurobiology of Disease, Cell Death and Disease, Glia, Molecular and Cellular Life Sciences, European Journal of Neuroscience, British Journal of Pharmacology, CNS Drugs, Journal of Neurochemistry, Cell Biology and Toxicology, Stem Cell Reviews and Reports, Febs Journal, Neuropharmacology, Amino Acids, Plos One. Associate Editor di Frontiers in Neurodegeneration, una sezione di "Frontiers in Neurology and Psychiatry".
GRANTS	Austrian Science Fund (FWF); French National Research Agency (ANR); Fondation pour la Recherche Médicale (FRM); AFM-Téléthon; Association pour la recherche sur la SLA (ARSLA); FISM; Slovak Research and Development Agency; National Research, Development and Innovation Office, Hungary (NRDI).

CAPACITÀ E COMPETENZE PERSONALI

MADRE LINGUA	ITALIANO
ALTRE LINGUE	INGLESE
• Capacità di lettura	OTTIMA
• Capacità di scrittura	OTTIMA
• Capacità di espressione orale	OTTIMA
ALTRE LINGUE	FRANCESE
• Capacità di lettura	BUONO
• Capacità di scrittura	BUONO
• Capacità di espressione orale	BUONO

.

.

***h* – index**	26 (by Scopus)
ORCID ID :	0000-0002-3346-1327
Scopus ID:	54931644600
CITAZIONI TOTALI	4060 (by Scopus)
PUBBLICAZIONI	*Lista delle pubblicazioni in riviste internazionali con "peer-review"*

1. Trotti, D., Volterra, A., Lehre, K.P., **Rossi, D.**, Gjesdal, O., Racagni, G., and Danbolt, N.C. (1995). Arachidonic Acid Inhibits a Purified and Reconstituted Glutamate Transporter Directly from the Water Phase and Not via the Phospholipid Membrane. ***J. Biol. Chem.***, 270, 9890 – 9895. doi: 10.1074/jbc.270.17.9890.
2. Trotti, D., **Rossi, D.**, Gjesdal, O., Levy, L.M., Racagni, G., Danbolt, N.C. and Volterra, A. (1996). Peroxynitrite inhibits glutamate transporter subtypes. ***J. Biol. Chem.***, 271, 5976-5979. doi: 10.1074/jbc.271.11.5976.
3. Trotti, D., Lodi Rizzini, B., **Rossi, D.**, Haugeto, O., Racagni, G., Danbolt, N.C. and Volterra, A. (1997). Neuronal and glial glutamate transporters possess an SH-based redox regulatory mechanism. ***Eur. J. Neurosci.***, 9, 1236-1243. doi: 10.1111/j.1460-9568.1997.tb01478.x.
4. Vesce S., Bezzi P., **Rossi D.**, Meldolesi J. and Volterra A. (1997). HIV-1 gp120 glycoprotein affects the astrocyte control of extracellular glutamate by both inhibiting the uptake and stimulating the release of the amino acid. ***FEBS Lett.***, 411, 107-109. doi: 10.1016/s0014-5793(97)00674-1.
5. Bezzi, P., Carmignoto, G., Pasti, L., Vesce, S., **Rossi, D.**, Lodi Rizzini, B., Pozzan, T. and Volterra, A. (1998). Prostaglandins stimulate calcium-dependent glutamate release in astrocytes. ***Nature***, 391, 281-285. doi: 10.1038/34651.
6. **Rossi, D.**, Cozzio, A., Flechsig, E., Klein, M.A., Rülicke, T., Aguzzi, A. and Weissmann, C. (2001). Onset of ataxia and Purkinje cell loss in PrP null mice inversely correlated with Dpl level in brain. ***EMBO J.***, 20, 694-702. doi: 10.1093/emboj/20.4.694.
7. Montrasio, F., Cozzio A., Flechsig, E., **Rossi, D.**, Klein, M.A., Rülicke, T., Raeber, A.J., Vosshenrich, C.A.J., Proft, J., Aguzzi A. and Weissmann C. (2001). B lymphocyte-restricted expression of prion protein does not enable prion replication in prion protein knockout mice. ***Proc. Natl. Acad. Sci. USA***, 98, 4034-4037. doi: 10.1073/pnas.051609398.
8. Weissmann, C., Enari, M., Klöhn, P.C., **Rossi, D.** and Flechsig, E. (2002). Transmission and Propagation of Prions. ***J. Infect. Dis.*** 186 Suppl 2:S157-S165. doi: 10.1086/344575.
9. Weissmann, C., Enari, M., Klöhn, P.C., **Rossi, D.** and Flechsig, E. (2002). Transmission of Prions. ***Proc. Natl. Acad. Sci. USA***, 99, 16378-162383. doi: 10.1073/pnas.172403799.
10. Weissmann, C., Enari, M., Klöhn, P.C., **Rossi, D.** and Flechsig, E. (2002). Molecular Biology of Prions. ***Acta Neurobiol. Exp. (Warsz)***, 62(3), 153-166.
11. Flechsig, E., Hegyi, I., Leimeroth, R., Zuniga, A., **Rossi, D.**, Cozzio, A., Schwarz, P., Rülicke, T., Götz, J., Aguzzi, A. and Weissmann, C. (2003). Expression of truncated PrP targeted to Purkinje cells of PrP knockout mice causes Purkinje cell death and ataxia. ***EMBO J.***, 22, 3095-3101. doi: 10.1093/emboj/cdg285.
12. Anderson, L.*****, **Rossi, D.***, Linehan, J., Brandner, S., and Weissmann C. (2004). Transgene-driven expression of the Doppel protein in Purkinje cells causes Purkinje cell degeneration and motor impairment. ***Proc. Natl. Acad. Sci. USA***, 101, 3644- 3649. doi: 10.1073/pnas.0308681101. ***Contributed equally to this work**
13. **Rossi, D.**, Brambilla, L., Valori, C., Bezzi, P., Giaccone, G, Capobianco, R., Mangieri, M. , Kingston A. and Volterra A. (2005). Defective TNFalpha-dependent control of astrocyte glutamate release in a transgenic mouse model of Alzheimer's disease. ***J. Biol. Chem.,*** 280, 42088-42096. doi: 10.1074/jbc.M504124200.
14. Vesce, S., **Rossi, D.**, Brambilla L. and Volterra, A. (2007). Glutamate release from astrocytes in physiological conditions and in neurodegenerative disorders characterised by neuroinflammation. ***Int Rev Neurobiol.***, 82, 57-71. doi: 10.1016/S0074-7742(07)82003-4.
15. **Rossi, D.***, Brambilla, L., Valori, C.F., Crugnola, A., Roncoroni, C., Yokota, T., Bredesen, D.E., and Volterra A. (2008). Focal damage of astrocytes in amyotrophic lateral sclerosis. ***Cell Death Differ.***, 15, 1691-1700. doi: 10.1038/cdd.2008.99. ***Corresponding author**
16. Barenco, M.G., Valori, C., Roncoroni, C., Loewer, J., Montrasio, F., **Rossi, D.** (2009). Deletion of the amino-terminal domain of the prion protein does not impair prion protein-dependent neuronal differentiation and neuritogenesis. ***J Neurosci Res.***, 87, 806-819. doi: 10.1002/jnr.21894.
17. **Rossi, D.** and Volterra, A. (2009). Astrocytic dysfunction: insights on the role in neurodegeneration. ***Brain Res Bull.***, 80(4-5):224-32. doi: 10.1016/j.brainresbull.2009.07.012.
18. **Rossi, D.,** Martorana, F., Brambilla, L. (2011). Implications of Gliotransmission for the

Pharmacotherapy of CNS Disorders. ***CNS Drugs***, 25(8), 641-658. doi: 10.2165/11593090-000000000-00000.

19. Martorana F., Brambilla, L., Valori C.F., Bergamaschi, C., Roncoroni, C., Aronica, E., Volterra, A., Bezzi, P., and **Rossi D.** (2012). The BH4 domain of Bcl-X_L rescues astrocyte degeneration in Amyotrophic Lateral Sclerosis by modulating intracellular calcium signals. ***Hum Mol Genet.***, 21(4), 826-840. Epub 2011 Nov 18. doi: 10.1093/hmg/ddr513.
20. Benedusi, V., Martorana, F., Brambilla, L., Maggi, A., and **Rossi, D.** (2012). The Peroxisome Proliferator-Activated Receptor γ (PPARγ) controls natural protective mechanisms against lipid peroxidation in Amyotrophic Lateral Sclerosis. ***J. Biol. Chem.***, 287(43), 35899-35911. doi: 10.1074/jbc.M112.366419.
21. Brambilla, L., Martorana, F., and **Rossi, D.** (2013). Astrocyte signalling and neurodegeneration: new insights into CNS disorders. ***Prion***, 7(1), 28-36. doi: 10.4161/pri.22512.
22. Valori, C.F., Brambilla, L., Martorana, F., and **Rossi, D.** (2014). The Multifaceted Role of Glial Cells in Amyotrophic Lateral Sclerosis. ***Cell Mol Life Sci.***, 71(2), 287-297. doi: 10.1007/s00018-013-1429-7.
23. Pansarasa, O., **Rossi, D.**, Berardinelli, A., Cereda, C. (2014). Amyotrophic lateral sclerosis and skeletal muscle: an update. ***Mol Neurobiol.,*** 49(2), 984-990. doi: 10.1007/s12035-013-8578-4.
24. **Rossi, D.** (2015). Astrocyte physiopathology: at the crossroads of intercellular networking, inflammation and cell death. ***Prog Neurobiol***., 130, 86-120. doi: 10.1016/j.pneurobio.2015.04.003.
25. Martorana, F., Guidotti, G., Brambilla, L., **Rossi D.** (2015). Withaferin A inhibits nuclear factor-kappaB-dependent pro-inflammatory and stress response pathways in the astrocytes. ***Neural Plasticity***, 2015:381964. doi: 10.1155/2015/381964.
26. Brambilla, L., Guidotti, G., Martorana, F., Iyer, A.M., Aronica, E., Valori, C.F., **Rossi D.** (2016). Disruption of the astrocytic TNFR1-GDNF axis accelerates motor neuron degeneration and disease progression in amyotrophic lateral sclerosis. ***Hum Mol Genet.,*** 25(14), 3080-3095. doi: 10.1093/hmg/ddw161.
27. Guidotti, G., Brambilla, L., and **Rossi, D.** (2017). Cell-penetrating peptides: from basic research to clinics. ***Trends in Pharmacol Sci***, 38(4), 406-424. doi: 10.1016/j.tips.2017.01.003.
28. **Rossi, D.**, Volanti, P., Brambilla, L., Colletti, T., Spataro, R., and La Bella V. (2018). CSF Neurofilament Proteins as diagnostic and prognostic biomarkers for Amyotrophic Lateral Sclerosis. ***J Neurol.***, 265(3), 510-521. doi: 10.1007/s00415-017-8730-6.
29. Stanga, S., Brambilla, L., Tasiaux, B, Dang., H.A., Ivanoiu., A., Octave, J.N., **Rossi, D.**, van Pesch, V. and Kienlen-Campard P. (2018). A role for GDNF and soluble APP as biomarkers of Amyotrophic Lateral Sclerosis pathophysiology. ***Front Neurol.***, 2018 May 30;9:384. doi: 10.3389/fneur.2018.00384.
30. Brambilla, L., Martorana, F., Guidotti, G., and **Rossi, D.** (2018). Dysregulation of Astrocytic HMGB1 Signaling in Amyotrophic Lateral Sclerosis. ***Front Neurosci.***, 29 August 2018. doi: 10.3389/fnins.2018.00622.
31. Guidotti, G. Brambilla, L., and **Rossi, D.** (2019). Peptides in clinical development for the treatment of brain tumors. ***Curr Opin Pharmacol.***, 47, 102–109. doi: 10.1016/j.coph.2019.02.007.
32. Valori, C.F., Guidotti, G., Brambilla, L., and **Rossi, D.** (2019). Astrocytes: Emerging Therapeutic Targets in Neurological Disorders. ***Trends Mol Med.***, 25(9), 750-759. doi: 10.1016/j.molmed.2019.04.010.
33. Valori, C.F., Guidotti, G., Brambilla, L., and **Rossi, D.** (2019). Astrocytes in Motor Neuron Diseases. ***Adv Exp Med Biol.***, 1175, 227-272. doi: 10.1007/978-981-13-9913-8_10.
34. Norante, R.P., Peggion, C., **Rossi, D.**, Martorana, F., De Mario, A., Lia, A., Massimino, M.L., and Bertoli, A. (2019). ALS-Associated SOD1(G93A) Decreases SERCA Pump Levels and Increases Store-Operated Ca2+ Entry in Primary Spinal Cord Astrocytes from a Transgenic Mouse Model. ***Int J Mol Sci***., Oct 17;20(20). pii: E5151. doi: 10.3390/ijms20205151.
35. Guidotti, G., Brambilla, L., and **Rossi, D.** (2020). Exploring novel molecular targets for the treatment of high-grade astrocytomas using peptide therapeutics: an overview. ***Cells***, 9, 490; doi:10.3390/cells9020490.
36. Guidotti, G., Scarlata, C., Brambilla, L., and **Rossi, D.** (2021). Tumor Necrosis Factor alpha in Amyotrophic Lateral Sclerosis : Friend or Foe? ***Cells***, 10, 518; doi: 10.3390/cells10030518.
37. Cutarelli, A., Martínez-Rojas, V.A., Tata, A., Battistella, I., **Rossi, D.**, Arosio, D., Musio, C., and Conti, L. (2021). A Monolayer System for the Efficient Generation of Motor Neuron Progenitors and Functional Motor Neurons from Human Pluripotent Stem Cells. ***Cells***, 10, 1127; doi: 10.3390/cells10051127.

38. Valori, C.F., Possenti, A., Brambilla, L., and **Rossi, D.** (2021). Challenges and Opportunities of Targeting Astrocytes to Halt Neurodegenerative Disorders. ***Cells***, 10, 2019; doi: 10.3390/cells10082019.
39. Begenisic, T., Pavese, C., Aiachini, B., Nardone, A., and **Rossi, D.** (2021). Dynamics of biomarkers across the stages of traumatic spinal cord injury - Implications for neural plasticity and repair. ***Restor Neurol Neurosci.***, 39(5), 339-366; doi: 10.3233/RNN-211169.
40. Ferrari, F.*, **Rossi, D.***, Ricciardi, A.*, Morasso, C. Brambilla, L., Albasini, S., Vanna, R., Fassio, C., Begesenic, T., Loi, M., Bossi, D., Zaliani, A., Alberici, E., Lisi, C., Morotti, A., Cavallini, A., Mazzacane, F., Nardone, A., Corsi, F., Truffi, M. (2023). Quantification and prospective evaluation of serum NfL and GFAP as blood-derived biomarkers of outcome in acute ischemic stroke patients. ***J Cereb Blood Flow Metab.*** ; doi: 10.1177/0271678X231172520. ***Contributed equally to this work**
41. Valori, C.F., Sulmona, C., Brambilla, L., and **Rossi, D.** (2023). Astrocytes: dissecting their diverse roles in amyotrophic lateral sclerosis and frontotemporal dementia. ***Cells*** 12, 1450; doi:10.3390/cells12111450.
42. De martini, L.B., Sulmona, C., Brambilla, L., and **Rossi, D.** (2023). Cell-Penetrating Peptides as Valuable Tools for Nose-to-Brain Delivery of Biological Drugs. ***Cells***, 12, 1643; https://doi.org/10.3390/cells12121643.

Capitoli di libri

43. Trotti, D., Danbolt, N.C., Lodi Rizzini, B., Bezzi, P., **Rossi, D.**, Racagni, G. and Volterra, A. (1996). Glutamate transporters: molecular mechanisms of functional alteration and role in the development of excitotoxic neuronal injury.
    Neurodegenerative diseases, ed. Gary Fiskum, Plenum Press, New York.
44. Trotti, D., **Rossi, D.**, Lodi Rizzini, B., Bezzi, P., Danbolt, N.C., Racagni, G. and Volterra, A. (1996). Molecular mechanisms of functional alteration of glutamate transporters and relevance to neuropathology
    Preclinical and clinical strategies for the treatment of neurodegenerative, cerebrovascular and mental disorders, Int. Acad. Biomed. Drug Res. Basel, Karger, 11, 41-48.
45. Weissmann, C., Shmerling, D., **Rossi, D.**, Cozzio, A., Hegyi, I., Fischer, M., Leimeroth, R. and Flechsig, E. (2001). Structure-function analysis of prion protein.
    New challenges to health: the threat of virus infection, ed. G.L. Smith, W.L. Irving, J.W. McCauley, D.J. Rowlands, Cambridge University Press.
46. Weissmann, C., Flechsig, E., **Rossi, D.**, Enari, M. (2002). Molecular Genetics of Trasmissible Spongiform Encephalopathies: An Overview.
    Nova Acta Leopoldina, NF 87, Nr. 327, S. 15-24.
47. **Rossi, D.**, Bezzi, P., Domercq, M., Brambilla, L., Meldolesi, J., and Volterra, A. (2004). Contribution of Astrocyte Glutamate Release to Excitotoxicity.
    Excitotoxicity in Neurological Disorders: New therapeutic challenge. C. Ferrarese and F. Beal Eds, Kluwer Press.
48. **Rossi, D.** & Volterra, A. (2011). Astrocyte-Neuron Communication: What Goes Wrong in Pathology?
    Astrocytes: Wiring the Brain. E. Scemes and D.C. Spray Eds, CRC Press.
49. Valori, C.F., Brambilla, L., and **Rossi, D.** (2014). Amyotrophic Lateral Sclerosis: a glial perspective.
    Pathological potential of neuroglia: Possible new targets for medical intervention. V. Parpura and A. Verkhratsky Eds, Springer.

Estratti e presentazioni a congressi nazionali ed internazionali

50. Volterra, A., Trotti, D., Bezzi, P., Lodi Rizzini, B., **Rossi, D.** e Racagni, G.
    Trasportatori del glutammato: inibizione da acido arachidonico e radicali ossigeno via distinti meccanismi e ruolo nello sviluppo del danno neuroeccitotossico.
    VI Congresso della Società Italiana di Neuroscienze
    Milano (Italia), 25-28 giugno 1995
51. Volterra, A., Trotti, D., Bezzi, P., Lodi Rizzini, B., **Rossi, D.** e Racagni, G.
    Ruolo dei trasportatori del glutammato nello sviluppo del danno neuroeccitotossico.
    X Congresso Nazionale della Società Italiana Neuropsicofarmacologia
    Venezia (Italia), 27-29 settembre 1995
52. Volterra, A., Bezzi, P., Lodi Rizzini, B., Trotti, D., **Rossi, D.**, Racagni, G.
    Enhanced extracellular glutamate and delayed neurotoxicity in cortical neuroglial cocultures exposed to the glutamate uptake inhibitor PDC.
    8th ECNP CONGRESS (European college of Neuropsychopharmacology)

Venice (Italy), september 30-october 4, 1995.

53. Trotti, D., Danbolt, N.C., **Rossi, D.**, Racagni, G., Gjesdal, O., Storm-Mathisen, J. and Volterra, A.
SH- groups of cysteine residues on Glutamate transporters are critical for uptake activity.
1995 Annual Meeting, Society for Neuroscience
San Diego CA (USA), November 11-16, 1995
54. Volterra, A., Trotti, D., Lodi Rizzini, B., **Rossi, D.**, Bezzi, P., Danbolt, N.C., Racagni, G.
Neuronal and glial glutamate transporters contain an SH-based site responsible for redox modulation and oxidant vulnerability.
1996 Annual Meeting, Society for Neuroscience
Washington D.C. (USA), November 16-21, 1996
55. Lodi Rizzini, B., **Rossi, D.**,Trotti, D., Danbolt, N.C. e Volterra, A.
Regolazione ossido-riduttiva e vulnerabilità agli ossidanti dei trasportatori neuronali e gliali del glutammato.
Società Italiana di Neuroscienze
V Convegno Nazionale
Giovani Cultori delle Neuroscienze
Pisa (Italia), 12 - 14 dicembre 1996
56. Volterra, A., Trotti, D., Lodi Rizzini, B., **Rossi, D.**, Bezzi, P., Racagni, G., Danbolt, N.C.
Glutamate transporters are redox-sensitive: a link between oxidative and excitotoxic neuronal derangement.
XXVIII Congresso Nazionale della Società Italiana di Farmacologia
Bari (Italia), 30 aprile - 3 maggio 1997
57. **Rossi, D.**, Lodi Rizzini, B., Danbolt, N.C., Trotti, D. and Volterra, A.
Peroxynitrite-mediated inhibition of glutamate transporters: molecular aspects and neuropathological relevance.
First International Conference on the Chemistry and Biology of Peroxynitrite
Ascona (Switzerland), May 11-16, 1997
58. Volterra, A., Lodi Rizzini, B., **Rossi, D.**, Bezzi, P., Trotti, D., e Danbolt, N.C.
Modulazione redox e vulnerabilità agli ossidanti dei trasportatori astrocitari del glutammato nativi e ricombinanti.
Convegno "Fisiopatologia della Funzione Gliale"
Genova (Italia), 22-23 maggio 1997
59. Bezzi, P., Vesce, S., **Rossi, D.**, Meldolesi, J., Volterra, A.
La gp120 induce accumulo di glutammato extracellulare da colture astrocitarie: studio dei meccanismi coinvolti.
Convegno "Fisiopatologia della Funzione Gliale"
Genova (Italia), 22-23 maggio 1997
60. Volterra, A., Trotti, D., Lodi Rizzini, B., **Rossi, D.**, Bezzi, P. and Danbolt, N.C.
Glial and neuronal glutamate transporters contain an SH-based site responsible for redox modulation and oxidant vulnerability.
"Function of Glial Cells" Meeting
Bogensee near Berlin (Germany), June 7-10, 1997
61. Bezzi, P., Vesce, S., **Rossi, D.**, Lodi Rizzini, B., Podini, P., Meldolesi, J. and Volterra, A.
GP120 elevates extracellular glutamate in astrocyte cultures by combined induction of release and inhibition of uptake.
1997 Annual Meeting, Society for Neuroscience
New Orleans, La. (USA), October 25-30, 1997
62. Cozzio, A., **Rossi, D.**, Flechsig, E., Klein, M.A., Fischer, M., Büeler, H.R., Aguzzi, A. and Weissmann, C.
Does prion protein (PrP^C) ablation in mice elicit ataxia or motor impairment?
International Symposium "Characterization and Diagnosis of Prion Diseases in Animals and Man"
Tübingen (Germany), September 23-25, 1999
63. **Rossi, D.**, Cozzio, A., Flechsig, E., Klein, M.A., Aguzzi, A. and Weissmann, C.
Deficiency or overexpression of PrP does not lead to a deleterious phenotype.
Transmissible Spongiform Encephalopathies Workshop
Keele (United Kingdom), April 4-6, 2000
64. **Rossi, D.**, Cozzio, A., Flechsig, E., Klein, M.A., Aguzzi, A. and Weissmann, C.
Deficiency of PrP does not lead to a deleterious phenotype.
ELSO 2000
Geneva (Switzerland), September 2-6, 2000
65. **Rossi, D.**, Cozzio, A., Flechsig, E., Klein, M.A., Rülicke, T., Aguzzi, A. and Weissmann, C.
Deficiency of PrP does not lead to a deleterious phenotype.
3rd-VW Symposium on Conditional Mutagenesis

Berlin (Germany), October 9-10, 2000

66. Volterra, A., Cafè, C., Valori, C., Yakota, T., Bredesen, D. and **Rossi, D.**
Apoptosis of spinal cord astrocytes secondary to ALS-linked SOD1 mutations: mechanism, relevance for motor neuron degeneration and prospective pharmacological intervention.
XI Scientific Convention – Telethon 2002
Riva del Garda (Italy), November 24-26, 2002
67. **Rossi, D.**, Cafè, C., Valori, C., Yakota, T., Bredesen, D. and Volterra, A.
Apoptosis of spinal cord astrocytes secondary to ALS-linked SOD1 mutations.
31° Congresso della Società Italiana di Farmacologia
Trieste (Italy), June 26-29, 2003
68. Brambilla, L., **Rossi, D.**, Valori, C., Bezzi, P., Giaccone, G., Capobianco, R., Mangieri, M., Kingston, A. and Volterra, A.
Alteration of astrocyte calcium-dependent glutamate release in a transgenic mouse model of Alzheimer disease.
31° Congresso della Società Italiana di Farmacologia
Trieste (Italy), June 26-29, 2003
69. **Rossi, D.**, Valori, C., Cafè, C., Crugnola, A., Yokota, T., Bredesen, D. and Volterra, A.
Apoptosi di astrociti di midollo spinale secondaria a mutazioni della SOD1 associate alla SLA.
Congresso Nazionale della Società Italiana di Neuroscienze
Pisa (Italy), September 26-28, 2003
70. Brambilla, L., **Rossi, D.**, Valori, C., Bezzi, P., Giaccone, G., Capobianco, R., Mangieri M. and Volterra, A.
Alterazioni del rilascio calcio-dipendente di glutammato da astrociti in un modello transgenico della patologia di Alzheimer.
Congresso Nazionale della Società Italiana di Neuroscienze
Pisa (Italy), September 23-25, 2003
71. Volterra, A., Valori, C., Crugnola, A., Brambilla, L., Cafè, C., Yakota, T., Bredesen, D. and **Rossi, D.**
Apoptosis of spinal cord astrocytes secondary to ALS-linked SOD1 mutations: mechanism, relevance for motor neuron degeneration and prospective pharmacological intervention.
XII Scientific Convention – Telethon 2003
Riva del Garda (Italy), November 23-25, 2003
72. **Rossi, D.**, Valori, C., Crugnola, A. , Brambilla, L., Yokota, T., Bredesen, D. and Volterra, A.
Apoptosis of spinal cord astrocytes secondary to ALS-linked SOD1 mutations.
2nd European ALS Research Workshop
Nice (France) May 14-16, 2004
73. Volterra, A., Valori, C., Brambilla, L., Crugnola, A., Biondi, G., Cafè, C., Yokota, T., Bredesen, D. and **Rossi, D.**
Apoptosis of spinal cord astrocytes secondary to ALS-linked SOD1 mutations: mechanism, relevance for motor neuron degeneration and prospective pharmacological intervention.
XIII Scientific Convention – Telethon 2005
Salsomaggiore Terme (Italy), March 6-8, 2005
74. **Rossi, D.**, Brambilla, L., Valori, C.F., Flechsig, E., Volterra, A.
Impaired astrocyte glutamate release in a mouse model of prion diseases.
II International Symposium on The New Prion Biology: Basic Science, Diagnosis and Therapy
Venezia (Italy), April 7-9, 2005
75. Barenco, M.G., Valori, C., Schubert, A., Hammann, J., Crugnola, A., Loewer, J., Weissmann, C.,Montrasio, F., **Rossi, D.**
Generation and characterization o f a novel PrP knockout cell line.
II International Symposium on The New Prion Biology: Basic Science, Diagnosis and Therapy
Venezia (Italy), April 7-9, 2005
76. **Rossi, D.**, Valori, C., Brambilla, L., Crugnola, A., Biondi, G., Yokota, T., Bredesen, D. and Volterra, A.
Apoptosis of spinal cord astrocytes secondary to the expression of ALS-linked mutant SOD1s: new potential targets for therapeutic approaches.
32° Congresso Nazionale della Società Italiana di Farmacologia
Napoli (Italy), June 1-4, 2005
77. **Rossi, D.**, Brambilla, L., Valori, C.F., Flechsig, E., Volterra, A.
Impaired glutamate-mediated glial-neuron cross-talk in a mouse model of prion diseases.

EMBO fellows meeting 2005
Heidelberg (Germany), June 17-20, 2005

78. **Rossi, D.**
Inflammation and classical neurotransmission
3rd Conference on Epileptogenesis
Venice (Italy), July 28-30, 2005

79. **Rossi, D.**, Brambilla, L., Valori, C.F., Giaccone, G., Kingston, A. E., Bloc, A., Bezzi, P., and Volterra A.
Altered astrocyte-neuron cross-talk in animal models of Alzheimer's disease and ALS.
7° Convegno FISV
Riva del Garda (Italy), September 22-25, 2005

80. **Rossi, D.**, Valori, C., Brambilla, L., Crugnola, A., Biondi, G., Yokota, T., Bredesen, D. and Volterra, A.
Apoptosis of spinal cord astrocytes secondary to the expression of ALS-linked mutant SOD1s: new potential targets for therapeutical approaches.
Congresso Nazionale della Società Italiana di Neuroscienze e Joint Italian_Swedish Neuroscience meeting
Ischia (Italy), October 1-4, 2005

81. Barenco, M.G., Valori, C., Schubert, A., Hammann, J., Crugnola, A., Loewer, J., Weissmann, C., Montrasio, F., **Rossi, D.**
Generation and characterization o f a novel PrP knockout cell line.
Prion 2005: Between fundamentals and society's needs
Düsseldorf (Germany), October 19-21, 2005

82. Barenco, M.G., Hammann, J., Valori, C., Crugnola, A., Loewer, J., Weissmann, C., Montrasio, F., **Rossi, D.**
The N-terminal domain of PrP^C is not necessary for the induction of neuronal differentiation.
2nd Dominique Dormont International Conference. Pathogenesis of Prion and Viral Infections.
Paris (France), December 1-3, 2005

83. **Rossi, D.**, Valori, C.F., Brambilla, L., Crugnola, A., Biondi, G., Yokota, T., Bredesen, D.E., and Volterra, A.
Apoptosis of spinal cord astrocytes secondary to ALS-linked SOD1 mutations.
First annual meeting of the NeuroNE consortium
London (United Kingdom), February 9-12, 2006

84. **Rossi, D.**, Brambilla, L., Valori, C.F., Crugnola, A., Giaccone, G., Kingston, A.E., Flechsig, E., Bezzi, P., Volterra, A.
Altered control of glial glutamate release in animal models of Alzheimer's and prion diseases.
57° Congresso Nazionale Società Italiana di Fisiologia
Ravenna (Italy), September 25-27, 2006
Published on Acta Physiologica, Volume 188, Supplement 652, S12-85.

85. Barenco, M.G., Valori, C., Hammann, J., Crugnola, A., Loewer, J., Weissmann, C., Montrasio, F., **Rossi, D.**
The N-terminal domain of the cellular prion protein is not necessary to induce neuronal differentiation and neurite outgrowth.
Prion 2006: Strategies, advances and trends towards protection of society
Turin (Italy), October 3-6, 2006

86. Valori, C.F., Brambilla, L., Crugnola, A., Roncoroni, C., Niccolini, F., Bonny, C., Volterra, A., and **Rossi, D.**
Glial implication in ALS pathogenesis: testing two innovative therapeutic approaches.
XIV Scientific Convention – Telethon 2007
Salsomaggiore Terme (Italy), March 12-14, 2007

87. **Rossi, D.**, Brambilla, L., Valori, C.F., Giaccone, G., Kingston, A.E., Flechsig, E., Bloc, A., Bezzi, P. and Volterra, A.
Alterations of the Ca^{2+}-dependent glial glutamate release in animal models of neurodegenerative disorders.
V Incontro dell'Istituto di Neuroscienze – CNR
Cagliari (Italy), June 3-5, 2007

88. **Rossi,D.**, Brambilla, L., Valori, C.F., Roncoroni, C., Crugnola, A., Yokota, T., Bredesen, D.E., and Volterra, A.
Focal Degeneration of Glutamate-Vulnerable Astrocytes in Amyotrophic Lateral Sclerosis.
19th International Symposium on ALS/MND
Birmingham (United Kingdom) November 3-5, 2008

89. Valori, C.F., Brambilla, L., Roncoroni, C., Martorana, F., Crugnola, A., Bonny, C., Volterra,

A. and **Rossi, D.**
Glial implication in ALS pathogenesis: testing two innovative therapeutic approaches.
XV Scientific Convention – Telethon 2009
Riva del Garda (Italy), March 9-11, 2009

90. **Rossi, D.**
Role of astroglia on motor neuron cell survival and death in ALS.
IV Meeting on the MOLECULAR MECHANISMS OF NEURODEGENERATION
Milan (Italy), May 8-10, 2009
91. **Rossi, D.**
Meccanismi molecolari: studi in modelli animali
La Sclerosi Laterale Amiotrofica: la presa in carico globale dal laboratorio di ricerca al letto del malato.
AISLA meeting
Asti (Italy) June 20, 2009
92. **Rossi, D.**, Brambilla, L., Valori, C.F., Roncoroni, C., Martorana, F., Crugnola, A., Bredesen, D.E., and Volterra A.
Astroglial degeneration in Amyotrophic Lateral Sclerosis
National Congress of the Italian Society for Neuroscience
Milan (Italy), October 2-5, 2009
93. Valori C.F., Martorana F., Brambilla L., Roncoroni C., Bonny C., Volterra A. and **Rossi D.**
Novel therapeutic strategies for Amyotrophic Lateral Sclerosis: testing the efficacy of cell-permeable peptides in preclinical models
European ALS Consortium Young Investigator Meeting
London (United Kingdom), July 28-30, 2010
94. **Rossi D.**, Martorana F., Valori C.F., Roncoroni C., Volterra A., Bezzi P., Brambilla L.
Glioprotective impact of cell-permeable peptides in preclinical models of Amyotrophic Lateral Sclerosis
9th Meeting of the European Network for the Cure of Amyotrophic Lateral Sclerosis
Hannover (Germany), May 13-15, 2011
95. Martorana F., Brambilla L., Valori C.F., Roncoroni C., Bergamaschi C., Volterra A., Bezzi P., **Rossi D.**
Aberrant intracellular Ca^{2+} signalling correlates with astrocyte degeneration in Amyotrophic Lateral Sclerosis
Joint congress of FEPS and Turkish Society of Physiological Sciences
Istanbul (Turkey), September 3-7, 2011
96. **Rossi D.**, Martorana F., Valori C.F., Roncoroni C., Bergamaschi C., Volterra A., Bezzi P., Brambilla L.
Glioprotective impact of cell-permeable peptides in preclinical models of Amyotrophic Lateral Sclerosis
10th European Meeting on Glial Cells in Health and Disease
Prague (Czech Republic), September 13-17, 2011
97. Martorana F., Brambilla L., Valori C.F., Bergamaschi C., Roncoroni C., Aronica E., Volterra A., Bezzi P., and **Rossi D.**
The BH4 domain of Bcl-XL rescues astrocyte degeneration in Amyotrophic Lateral Sclerosis by modulating intracellular calcium signals
International Symposium on "Biology and Translational Aspects of Neurodegeneration"
Venice (Italy), March 12-14, 2012
98. **Rossi D.**
Altered intracellular calcium signaling correlates with astrocyte degeneration in ALS
10th Annual European Network for the Cure of ALS Meeting
Dublin (Ireland), May 25-27, 2012
99. **Rossi D.**
Astrocyte degeneration in Amyotrophic Lateral Sclerosis: mechanism and rescue
4th Conference of the Mediterranean Neuroscience Society
Istanbul (Turkey), September 30 – October 3, 2012
100. Martorana F., Brambilla L., Valori C.F., Bergamaschi C., Roncoroni C., Aronica E., Volterra A., Bezzi P., and **Rossi D.**
Astrocyte degeneration correlates with aberrant intracellular calcium signalling in Amyotrophic Lateral Sclerosis
XI European Meeting on Glial Cells in Health and Disease
Berlin (Germany), July 3-6, 2013
101. Martorana F., Brambilla L., Valori C.F., Bergamaschi C., Roncoroni C., Aronica E., Volterra A., Bezzi P., and **Rossi D.**
Astrocyte signaling and neurodegeneration: the case of Amyotrophic Lateral Sclerosis
XV Congress of The Italian Society of Neuroscience

Rome (Italy), October 3-5, 2013

102. Martorana F., Brambilla L., Valori C.F., Bergamaschi C., Roncoroni C., Aronica E., Volterra A., Bezzi P., and **Rossi D.**
Regulation of IP_3-receptor-mediated calcium signaling and cell death by the BH4 domain of Bcl-X_L in ALS astrocytes.
24th International Symposium on ALS/MND
Milan (Italy), December 6-8, 2013.
103. **Rossi D.**, Martorana F., Guidotti G., and Brambilla L.
Developing innovative neuroprotective agents for the treatment of spinal muscular atrophy.
9th FENS Forum of Neuroscience
Milan (Italy) – July 5-9, 2014
104. Brambilla L., Martorana F., Guidotti G., Valori C.F., Bezzi P., and **Rossi D.**
Functional deficits of the astrocytes in Amyotrophic Lateral Sclerosis
XII European Meeting on Glial Cells in Health Disease
Bilbao (Spain) – July 15-18, 2015
105. **Rossi D.**
Peptide Therapeutics for the Treatment of Neurological Disorders
General States of Health Research – Italian Ministry of Health
Rome (Italy), April 27-28, 2016
91. Brambilla L., Martorana F., Guidotti G., Valori C.F., Bezzi P., and **Rossi D.**
Deciphering the pathological response of the astrocytes in Amyotrophic Lateral Sclerosis
European Network for the Cure of ALS Meeting 2016
Milan (Italy), May 19-21, 2016
106. Brambilla L., Guidotti G., Martorana F., Iyer A.M., Aronica E., Valori C.F., **Rossi D.**
Disruption of the astrocytic TNFR1-GDNF axis accelerates motor neuron degeneration and disease progression in amyotrophic lateral sclerosis
"More than neurons: toward a less neuronocentric view of brain disorders" Meeting
Turin (Italy), December 1-3, 2016
107. **Rossi D.**
Deciphering the astrocytic response in Amyotrophic Lateral Sclerosis
Workshop: "Human stem cells derived astrocytes as a new platform for studying neurological disorders"
Prague (Czech Republic), April 4, 2017
108. Brambilla L., Guidotti G., Martorana F., and **Rossi D.**
Developing innovative neuroprotective agents for the treatment of spinal muscular atrophy
E-Rare Data Sharing and Harmonization Workshop
Berlin (Germany), May 3-4, 2017
109. **Rossi D.**, Guidotti G., Martorana F., Brambilla L.
Developing innovative neuroprotective agents for the treatment of spinal musculare atrophy
21st International CureSMA Researcher Meeting
Orlando (FL, United States), June 29 – July 1, 2017
110. Guidotti G., Brambilla L., Martorana F., Iyer A.M., Aronica E., Valori C.F., **Rossi D.**
Motor neuron degeneration and disease progression in amyotrophic lateral sclerosis are accelerated by the disruption of the astrocytic TNFR1-GDNF axis.
XVII Congresso Nazionale SINS
Lacco Ameno (Italy), October 1-4, 2017
111. Brambilla L., Guidotti G., Martorana F., Aronica E., Valori C.F., Bezzi P. and **Rossi D.**
Astrocytes as cell targets for therapeutic intervention in ALS
38° Congresso Nazionale Società Italiana di Farmacologia
Rimini (Italy), October 25-28, 2017
112. Guidotti Giulia, Brambilla Liliana, Martorana Francesca, Iyer Anand m., Aronica Eleonora, Valori Chiara F., **Rossi Daniela**
Motor neuron degeneration and disease progression in amyotrophic lateral sclerosis are accelerated by the disruption of the astrocytic TNFR1-GDNF axis.
1st Braynstorming Research Assembly for Young Neuroscientist.
Genova (Italy), 29-30 Giugno 2018
113. **Rossi D.**, Guidotti G., Martorana F., Aronica E., Valori C.F., Bezzi P. and Brambilla L.
Astrocytes as cell targets for therapeutic intervention in ALS
Calcium Day 2018
Novara (Italy), July 2nd, 2018
114. Brambilla L., Guidotti G., Martorana F., Iyer A.M., Aronica E., Valori C.F., **Rossi D.**
Disruption of the astrocytic TNFR1-GDNF axis accelerates motor neuron degeneration and disease progression in amyotrophic lateral sclerosis
Associazione di Biologia Cellulare e del Differenziamento
Pavia (Italy), September 28-29, 2018

115. **Rossi D.**
Sviluppo di nuove terapie peptidiche per la SMA
SMA : Progressi e Nuove Sfide
Milan (Italy), October 11, 2018
116. Brambilla L., Martorana F., Guidotti G., **Rossi D.**
Dysregulation of astrocytic HMGB1 signaling in amyotrophic lateral sclerosis
"More than neurons: toward a less neuronocentric view of brain disorders" Meeting
Turin (Italy), November 29 - December 1, 2018
117. Brambilla L., Guidotti G., Martorana F., Iyer A.M., Aronica E., Valori C.F., **Rossi D.**
Disruption of the astrocytic TNFR1-GDNF axis accelerates motor neuron degeneration and disease progression in amyotrophic lateral sclerosis
29th International Symposium on ALS/MND
Glasgow (Scotland), December 7-9, 2018
118. Brambilla L., Guidotti G., Conti L., **Rossi D**
Developing combinatorial therapies for the treatment of Spinal Muscular Atrophy
6th Myology Congress
Bordeaux (France), March 25-28, 2019
119. **Rossi D.,** Guidotti G., Brambilla L.
Developing combinatorial therapies for the treatment of spinal muscular atrophy
23rd International SMA Researcher Meeting
Anaheim, CA (United States of America), June 28-30, 2019
120. Guidotti G., Brambilla L**.**, Martorana F., and **Rossi D.**
Dysregulation of astrocytic HMGB1 signaling in amyotrophic lateral sclerosis.
2st Braynstorming Research Assembly for Young Neuroscientist.
Milan (Italy), 14-16 Novembre 2019
121. Brambilla L**.**, Giudotti G., Martorana F., Iyer A.M., Aronica E., Valori C.F. and **Rossi D.**
Protective functions of neuroinflammation in amyotrophic lateral sclerosis
Convegno AriSLA 2019,
Milano (Italia), November 22-23,2019
122. **Rossi D.**, Guidotti G., Brambilla L.
Developing combinatorial therapies for the treatment of spinal muscular atrophy
2nd International Scientific Congress – SMA Europe
Paris (France), February 5-7, 2020
123. **Rossi D.**
Biomarcatori Molecolari
VI Corso SIN – Le malattie degenerative del sistema nervoso centrale
Virtual Meeting (Italy), October 22-23, 2020
124. **Rossi D.**
Motor neuron diseases: an overview of ALS and SMA
Motor Neuron Diseases. Understanding the Pathogenetic Mechanisms to develop Therapies
Virtual Meeting (Turin, Italy), November 6-7, 2020
125. **Rossi D.**
I neurofilamenti come biomarcatori nelle malattie neurodegenerative
Grandangolo 2021 – Un Anno di Neurologia
Virtual Meeting (Italy), January 29-30, 2021
126. **Rossi D.**
Lo stato infiammatorio in neurologia. Agente nemico o alleato terapeutico?
Convegno SINdem
Vicenza (Italy), April 22, 2022
127. Brambilla L., De Martini L., Possenti A., Karakashi F., Sulmona C., **Rossi D.**
Developing combinatorial therapies for the treatment of spinal musculare atrophy
3rd International Scientific Congress on spinal muscular atrophy (SMA Europe)
Barcelona (Spain), October 21-22, 2022

La sottoscritta è a conoscenza che, ai sensi dell'art. 76 del DPR 445/2000, le dichiarazioni mendaci, la falsità negli atti e l'uso di atti falsi sono puniti ai sensi del codice penale e delle leggi speciali. Inoltre, il sottoscritto autorizza al trattamento dei dati personali, secondo quanto previsto dalla Legge 196/03.

Pavia, 15/12/2023

NOME E COGNOME (FIRMA)

Daniela Rossi